Department of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.
Department of Radiation Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.
J Cancer Res Clin Oncol. 2021 Dec;147(12):3503-3516. doi: 10.1007/s00432-021-03765-6. Epub 2021 Aug 30.
Glioblastoma peritumoral edema (PE) extent is associated with survival and progression pattern after tumor resection and radiotherapy (RT). To increase tumor control, proton beam was adopted to give high-dose boost (> 90 Gy). However, the correlation between PE extent and prognosis of glioblastoma after postoperative high-dose proton boost (HDPB) therapy stays unknown. We intend to utilize the PE status to classify the survival and progression patterns.
Patients receiving HDPB (96.6 GyE) were retrospectively evaluated. Limited peritumoral edema (LPE) was defined as PE extent < 3 cm with a ratio of PE extent to tumor maximum diameter of < 0.75. Extended progressive disease (EPD) was defined as progression of tumors extending > 1 cm from the tumor bed edge.
After long-term follow-up (median 88.7, range 63.6-113.8 months) for surviving patients with (n = 13) and without (n = 32) LPE, the median overall survival (OS) and progression-free survival (PFS) were 77.2 vs. 16.7 months (p = 0.004) and 13.6 vs. 8.6 months (p = 0.02), respectively. In multivariate analyses combined with factors of performance, age, tumor maximum diameter, and tumor resection extent, LPE remained a significant factor for favorable OS and PFS. The rates of 5-year complete response, EPD, and distant metastasis with and without LPE were 38.5% vs. 3.2% (p = 0.005), 7.7% vs. 40.6% (p = 0.04), and 0% vs. 34.4% (p = 0.02), respectively.
The LPE status effectively identified patients with relative long-term control and specific progression patterns after postoperative HDPB for glioblastoma.
胶质母细胞瘤瘤周水肿(PE)的范围与肿瘤切除和放疗(RT)后的生存和进展模式有关。为了提高肿瘤控制率,采用质子束给予高剂量推量(>90Gy)。然而,术后高剂量质子推量(HDPB)治疗后 PE 范围与胶质母细胞瘤预后之间的相关性尚不清楚。我们打算利用 PE 状态对生存和进展模式进行分类。
回顾性评估接受 HDPB(96.6GyE)治疗的患者。局限性瘤周水肿(LPE)定义为 PE 范围<3cm,PE 范围与肿瘤最大直径的比值<0.75。广泛进展性疾病(EPD)定义为肿瘤从肿瘤床边缘延伸超过 1cm 的进展。
在生存患者(n=13)和无 LPE 患者(n=32)的长期随访(中位随访时间 88.7 个月,范围 63.6-113.8 个月)后,中位总生存期(OS)和无进展生存期(PFS)分别为 77.2 个月和 16.7 个月(p=0.004)和 13.6 个月和 8.6 个月(p=0.02)。在多变量分析中,结合表现、年龄、肿瘤最大直径和肿瘤切除程度等因素,LPE 仍然是 OS 和 PFS 的显著因素。有和无 LPE 的 5 年完全缓解率、EPD 和远处转移率分别为 38.5%和 3.2%(p=0.005)、7.7%和 40.6%(p=0.04)和 0%和 34.4%(p=0.02)。
LPE 状态可有效识别胶质母细胞瘤术后接受 HDPB 治疗后具有相对长期控制和特定进展模式的患者。